Long-term treatment with slow release oxprenolol alone, or in combination with other drugs: effects on blood pressure, lipoproteins and exercise performance

Australian and New Zealand Journal of Medicine
L A SimonsL Viles

Abstract

Twenty-eight patients with mild essential hypertension were treated with placebo for six weeks and then with active medication for a further 32 weeks. Twelve patients were well-controlled with 160-320 mg/day of slow release oxprenolol alone, 12 required oxprenolol and chlorthalidone, and four also required hydrallazine. beta-adrenergic blockade reduced the basal level of plasma free fatty acid (FFA) by 41%. A sub-maximal exercise test reduced the level of FFA by 34% during placebo treatment. The same exercise test during beta-blockade reduced the already lowered basal FFA level by a further 45%. Only female subjects experienced exercise-induced leg fatigue during beta-blockade. They always had higher FFA levels than males, but the relative changes in FFA concentration were similar in both sexes. Exercise testing induced a 52 mmHg rise in systolic blood pressure, but this was reduced to only 14 mmHg during treatment. Patients controlled on oxprenolol alone showed no significant change in plasma lipid and lipoprotein levels. Those patients ultimately requiring combination drug therapy experienced a statistically significant rise in plasma triglycerides and a significant fall in high density lipoprotein cholesterol. The biological...Continue Reading

References

Jul 9, 1977·British Medical Journal·A NilssonB Hökfelt
Apr 15, 1978·British Medical Journal·J ShawA S Hua
Aug 1, 1979·British Journal of Clinical Pharmacology·S B PearsonJ M Patrick
Dec 15, 1979·British Medical Journal·R Stone
Jan 7, 1978·Lancet·G BerglundJ Wikstrand
Oct 1, 1976·Metabolism: Clinical and Experimental·N TanakaT Kanehisa
Aug 5, 1978·British Medical Journal·A HelgelandI Holme
Nov 25, 1978·British Medical Journal·D Streja, D Mymin
Oct 1, 1979·Australian and New Zealand Journal of Medicine·S D AndersonG Nyberg
Nov 24, 1979·British Medical Journal·J C ForfarR E Cull
Oct 1, 1979·Postgraduate Medical Journal·I W BeinartC W Havard
Sep 10, 1977·British Medical Journal·H J Waal-Manning, F O Simpson
May 15, 1975·Clinica Chimica Acta; International Journal of Clinical Chemistry·D Sampson, W J Hensley
Apr 2, 1981·The New England Journal of Medicine·UNKNOWN Norwegian Multicenter Study Group
Jun 1, 1981·Atherosclerosis·L A Carlson, L E Böttiger
Nov 1, 1981·Atherosclerosis·L A SimonsD M Beins
May 1, 1980·Clinical and Experimental Pharmacology & Physiology·J D EnglandM Carlton

❮ Previous
Next ❯

Citations

Jun 24, 2015·Current Opinion in Lipidology·Tarza J SiahmansurHandrean Soran

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.